Oct 5 2010
Sirius Genomics, a developer of companion diagnostics, announced today that it has signed its second Contribution Agreement with the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP).
This research funding will be applied to discovery of genomic biomarkers that are predictive of patient response to therapeutics used in critical care medicine leading to improved disease outcomes.
Chris Wagner, President and CEO of Sirius Genomics, comments, "NRC-IRAP's continued support reflects the Canadian Government's commitment to scientific innovation and support for the growth of Canadian companies. Funding from NRC-IRAP will help us advance our pipeline of companion diagnostics."
New genetic variants could raise a woman's risk of cervical cancer from HPV infections